{'52WeekChange': 0.7269231,
 'SandP52WeekChange': 0.0644362,
 'address1': '561 Eccles Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 27,
 'askSize': 1000,
 'averageDailyVolume10Day': 142525,
 'averageVolume': 164409,
 'averageVolume10days': 142525,
 'beta': None,
 'beta3Year': None,
 'bid': 20,
 'bidSize': 1000,
 'bookValue': 5.422,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 26.621,
 'dayLow': 21.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -8.906,
 'enterpriseToRevenue': 437.424,
 'enterpriseValue': 408991072,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 26.502285,
 'fiftyTwoWeekHigh': 51.21,
 'fiftyTwoWeekLow': 10.52,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13622961,
 'forwardEps': -3.08,
 'forwardPE': -7.2889614,
 'fromCurrency': None,
 'fullTimeEmployees': 68,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.028269999,
 'heldPercentInstitutions': 0.70868,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/rapt.com',
 'longBusinessSummary': 'RAPT Therapeutics, Inc., a clinical-stage '
                        'immunology-based biopharmaceutical company, focuses '
                        'on discovering, developing, and commercializing oral '
                        'small molecule therapies for patients with unmet '
                        'needs in oncology and inflammatory diseases. Its lead '
                        'oncology drug candidate is FLX475, an oral small '
                        'molecule C-C motif chemokine receptor 4 antagonist '
                        'that is in the Phase 2 portion of a Phase 1/2 '
                        'clinical trial to evaluate as a monotherapy and in '
                        'combination with pembrolizumab in patients with '
                        "various types of charged tumors. The company's lead "
                        'inflammation drug candidate is RPT193 to selectively '
                        'inhibit the migration of type 2 T helper cells into '
                        'allergically-inflamed tissues. It is also pursuing a '
                        'range of targets, including general control '
                        'nonderepressible 2 and hematopoietic progenitor '
                        'kinase 1 that are in the discovery stage of '
                        'development. The company was formerly known as FLX '
                        'Bio, Inc. and changed its name to RAPT Therapeutics, '
                        'Inc. in May 2019. RAPT Therapeutics, Inc. was founded '
                        'in 2015 and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'RAPT Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 547189568,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_274079952',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -46948000,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 489 9000',
 'previousClose': 25.21,
 'priceHint': 2,
 'priceToBook': 4.1405387,
 'priceToSalesTrailing12Months': 585.2295,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 26.621,
 'regularMarketDayLow': 21.9,
 'regularMarketOpen': 25.26,
 'regularMarketPreviousClose': 25.21,
 'regularMarketPrice': 25.26,
 'regularMarketVolume': 118566,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24373700,
 'sharesPercentSharesOut': 0.0341,
 'sharesShort': 831236,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 179888,
 'shortName': 'RAPT Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0762,
 'shortRatio': 3.43,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'RAPT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.7,
 'twoHundredDayAverage': 24.113993,
 'volume': 118566,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.rapt.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}